Table 4.

Association of combination vasopressor versus monotherapy on mortality

Characteristics	No. died/no. at risk	Unadjusted OR (95% CI)	P	aOR* (95% CI)	P
1 vasopressor (reference)	1,572/2,355
2 vs. 1 vasopressor	522/618	1.3 (1.10–1.45)	<0.001	0.91 (0.78–1.06)	0.2
≥3 vs. 1 vasopressor	142/104	2.5 (1.58–2.66)	<0.001	0.93 (0.68–1.27)	0.6

*Models were fitted on 5,313 patients with complete data and adjusted for differences in age, sex, race, Charlson comorbidity score, history of hypertension, use of mechanical ventilation, APACHE III score, AKI severity within 7 days of ICU admission, median dose of norepinephrine equivalent dose, and median MAP in the first 6 h. Hosmer-Lemeshow goodness-of-fit C statistic, 0.12 (area under the receiver operating characteristic curve = 0.74; 95% CI, 0.73–0.76).